Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21044072 | 0.85 | HDAC1 (0.39) | HDAC1KMT2AMAPK1MEN1NPSR1 | |
| SCHEMBL11922827 | 0.83 | AKR1C1 (0.41) | HDAC1KMT2AMAPK1MEN1NPSR1 | |
| SCHEMBL5516039 | 0.81 | TLR7 (0.36) | HDAC1KMT2AMAPK1MEN1ABHD16A | |
| SCHEMBL21076995 | 0.77 | CTPS1 (0.41) | NPSR1NPC1RAB9A | |
| SCHEMBL20640304 | 0.77 | MEN1 (0.50) | KMT2AMAPK1MEN1NPC1RAB9A | |
| SCHEMBL21076997 | 0.76 | RAB9A (0.34) | HDAC1NPSR1GAANPC1RAB9A | |
| SCHEMBL12002672 | 0.74 | MAPK1 (0.36) | HDAC1KMT2AMAPK1MEN1NPSR1 | |
| SCHEMBL2588976 | 0.73 | LMNA (0.35) | KMT2AMAPK1MEN1NPSR1GAA | |
| SCHEMBL22869122 | 0.72 | PDE5A (0.38) | HDAC1KMT2AMAPK1MEN1ALDH1A1 | |
| SCHEMBL32663074 | 0.71 | CTPS1 (0.43) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | HDAC1 854/4885KMT2A 2206/4885MAPK1 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.